Rucaparib (AG-014699,PF-01367338) phosphate

製品コードS1098

Rucaparib (AG-014699,PF-01367338) phosphate化学構造

分子量(MW):421.36

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

サイズ 価格(税別)  
JPY 24200
JPY 21900
JPY 36800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(29)

製品安全説明書

PARP阻害剤の選択性比較

生物活性

製品説明 Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
特性 The first PARP inhibitor used in clinical trials combined with temozolomide.
ターゲット
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外試験

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 NXGwdmFUTnWwY4Tpc44hSXO|YYm= Ml:5NE4yNzFxNUCwM|ExODBibl2= M2r1fIlvcGmkaYTzJHBCWlBiYXP0bZZqfHliYYSgd5RienSrbnegZ49v[2W{boTyZZRqd25ib3[gOVAxKG6P MkPCNlUyOjh2NUW=
BT474 M2fIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLaVm82ODBibl2= NXPuc5hLOTEkgKOxOeKh\A>? MkTKdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> MUCyOVEzQDR3NR?=
SKBR3 NWrFZpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnXXm82ODBibl2= M2PhPFEx6oDVMUZCpIQ> NGTtNVNz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 Mnz5NlUyOjh2NUW=
AU565 M3TVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXnOVAxKG6P MlPTNVDjiJNzNdMg[C=> MnTTdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> MVWyOVEzQDR3NR?=
EFM192A M3\QPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfaR5JTPTByIH7N NFLwRm4yOOLCk{G1xsBl MVXy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKHSqZTDmc5VzKGyrbnXzJIFv\CC|aXfubYZq[2GwdHz5 NFjUTmwzPTF{OES1OS=>
MDA-MB-231 M3PLfWZ2dmO2aX;uJGF{e2G7 MlKwNVAwOjBxNECg{txO NEfLbXUzPCCq NWTPWm81cW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEHTV4czPDR{MEG1Ni=>
MDA-MB-231 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmHhNE4yNTRyIN88US=> MoX0NlQhcA>? MXnJR|Ux6oDLPfMAjVE4Njd5wrFOwG0> MmHSNlQ1OjBzNUK=
MDA-MB-231 M2XYXmFxd3C2b4Ppd{BCe3OjeR?= MVGxNE8zOC92MDFOwG0> MoPuNlQhcA>? NHPEWIpqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 MoPBNlQ1OjBzNUK=
MDA-MB-231 M1TDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\lNVAwOjBxNECg{txO NVnhfmpJOjRiaB?= MUnicI9kc3NiY3XscEBkgWOuZTDwdo9oemW|c3nvckBqdiCJMj;NJJBp[XOn MVyyOFQzODF3Mh?=
H460 M{XY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWC0NFAhdk1? NUW0cnpHOjUEoHi= M3jDbIlv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 NH;vbFMzPDRzMU[xNS=>
A549  NXPPTGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlXGVNPDByIH7N M4rJeFI1yqCq MmfPbY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm= NGT1NIYzPDRzMU[xNS=>
DT40 MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlexTWM2OD1{MTDuUS=> MofrNlQ{PTZ6MUO=
DU145 NWHrZWh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnRTZhKSzVyPUG4JI5O MlvmNlQ{PTZ6MUO=
COLO704 NXzaV3p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwNUKgxtEhOC54NzFOwG0> MWCyN|czQTRyMh?=
OVMANAb M3\SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW0TWM2OD1{LkW4JOKyKDBwM{ig{txO MWOyN|czQTRyMh?=
OV177 M4PyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPFV3lKSzVyPUKuO|ghyrFiMD63NUDPxE1? NW\4bGdVOjN5Mkm0NFI>
OAW28 NVrEWFhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTNwNkGgxtEhOC5{ODFOwG0> NHjEVoYzOzd{OUSwNi=>
OVSAHO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jQXGlEPTB;Mz62OEDDuSByLkOzJO69VQ>? M2LSUFI{PzJ7NECy
OVKATE MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULYeVZmUUN3ME2zMlY1KMLzIEGuO|kh|ryP MUmyN|czQTRyMh?=
OVCAR3 NEHsUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwN{SgxtEhOC52MDFOwG0> MWWyN|czQTRyMh?=
PEO14 M3LodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTNwOESgxtEhOC55NjFOwG0> NX3aS5RROjN5Mkm0NFI>
A2780 NETFXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULTPZR3UUN3ME2zMlk1KMLzIECuNlUh|ryP NFmwbWkzOzd{OUSwNi=>
OVTOKO M2XWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HRVmlEPTB;ND6xOEDDuSBzLkWzJO69VQ>? NIC0dYczOzd{OUSwNi=>
KURAMOCHIb MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwM{SgxtEhOC5{OTFOwG0> NVLtSoE5OjN5Mkm0NFI>
TOV21G NF6xRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTVwMEegxtEhOS5|MDFOwG0> NV;ZUYZJOjN5Mkm0NFI>
OVISE NWPIOVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHLVG5KSzVyPUWuOlghyrFiMD6yN{DPxE1? NWLKRplSOjN5Mkm0NFI>
KK MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT3TWM2OD14LkG1JOKyKDFwNEKg{txO NWjYOllVOjN5Mkm0NFI>
RMUGS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPQTWM2OD15LkCzJOKyKDFwOEOg{txO NYm5eJU5OjN5Mkm0NFI>
PEO6 NXf5NWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPIRlZKSzVyPUeuNFYhyrFiMD63OEDPxE1? M3vxelI{PzJ7NECy
OVCA429 NWLhTHlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL4bWJKSzVyPUiuNlkhyrFiMT62OEDPxE1? NHHISWYzOzd{OUSwNi=>
OV167 NHewNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTFTWM2OD16LkOzJOKyKDFwMUig{txO MlG2NlM4Ojl2MEK=
RMG1 M4rEZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHmTWM2OD17LkOyJOKyKDJwM{[g{txO MVqyN|czQTRyMh?=
OVCAR5 M{ntdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTlwNUCgxtEhOi53OTFOwG0> Mn7YNlM4Ojl2MEK=
EFO21 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHRTWM2OD17LkmyJOKyKDFwOEeg{txO NFzGTJQzOzd{OUSwNi=>
ES2 NELiRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GyTGlEPTB;MUCuNVIhyrFiMT6yN{DPxE1? M{PUU|I{PzJ7NECy
Tyk-nu NEfESYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jEXGlEPTB;MUCuNlAhyrFiMT6xNkDPxE1? M3WyVlI{PzJ7NECy
CAOV3 M{\wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHO[|REUUN3ME2xNE4{PyEEsTCwMlg4KM7:TR?= M{LDT|I{PzJ7NECy
OV207 NYfKS5J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\aRndKSzVyPUGyMlI4KMLzIECuN|Ih|ryP MVOyN|czQTRyMh?=
HEY M3S1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIruNmxKSzVyPUGzMlAyKMLzIECuO|Uh|ryP MlO4NlM4Ojl2MEK=
DOV13 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRjF3IN88US=> MlzUNlM4Ojl2MEK=
EFO27 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzzdFRoUUN3ME6xOUDPxE1? MmW3NlM4Ojl2MEK=
HEY C2 NGW5eohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjSPHZ5UUN3ME6xOUDPxE1? M1nnNVI{PzJ7NECy
KOC-7cc M1fjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UTWM2OD5zNTFOwG0> M3LQRVI{PzJ7NECy
MCASb MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4niT2lEPTB-MUWg{txO MVmyN|czQTRyMh?=
OAW42 NFT4dWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2V2lEPTB-MUWg{txO NV3ifY5vOjN5Mkm0NFI>
OV2008 MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rIXWlEPTB-MUWg{txO MU[yN|czQTRyMh?=
OV90 M2qxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrZW5FKSzVyPkG1JO69VQ>? MYeyN|czQTRyMh?=
OVCA420b MmPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRjF3IN88US=> M{SxO|I{PzJ7NECy
OVCA432 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPzTWM2OD5zNTFOwG0> MonONlM4Ojl2MEK=
PEA2 M4[5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\m[3lwUUN3ME6xOUDPxE1? M3[zT|I{PzJ7NECy
SKOV3 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f0Z2lEPTB-MUWg{txO NXnoXmFJOjN5Mkm0NFI>
TOV112D M3ryfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ud3ZTOC1|IN88US=> NEjpSIZKSzVyPkG1JO69VQ>? NWriWI5wOjN5Mkm0NFI>
C4-2 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX4SldsOC1|IN88US=> MkjzNVQh\A>? MUXEUXNQ NIflWVdl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 MnLnNlM2PjV{NES=
PC3 NFvVbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnyVFdMOC1|IN88US=> MkjmNVQh\A>? MVfEUXNQ NWDMdFE5\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= NGS0XXAzOzV4NUK0OC=>
DU145 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\2OFAuOyEQvF2= MnvpNVQh\A>? NGHnVplFVVOR NXXIPVF2\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?= M4XFZVI{PTZ3MkS0
VCaP  NUPjco97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDnNE0{KM7:TR?= NUmzT5loOTRiZB?= NFnaNodFVVOR MkXE[IVkemWjc3XzJINwdG:weTDueY1j\XJiZH;z[UBl\XCnbnTlcpRtgQ>? MonTNlM2PjV{NES=
LNCaP  M1\yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjodlExNTNizszN M{HDN|E1KGR? M1\2c2ROW09? M{T1NYRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? MYmyN|U3PTJ2NB?=
MDA-MB-468 M2PWdmNmdGxiVnnhZoltcXS7IFHzd4F6 MV3JR|UxRTlwNzFOwG0> MoDCNlI3PzhzNkG=
MDA-MB-231 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mo\0TWM2OD1zMzFOwG0> NVj5d257OjJ4N{ixOlE>
Cal-51 NIm4cJVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFS4O|lKSzVyPUiuOkDPxE1? MmHzNlI3PzhzNkG=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

27960087 24085845
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

30589644 27515310 23565244
体内試験 Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Ki Determination:

Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
細胞試験: [4]
+ 展開
  • 細胞株: D425Med, D283Med and D384Med cells
  • 濃度: 0.4 μM
  • 反応時間: 3 or 5 days
  • 実験の流れ: Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: CD-1 nude mice bearing established D283Med xenografts
  • 製剤: Normal saline
  • 投薬量: 1 mg/kg
  • 投与方法: One or four daily by i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS No. 459868-92-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03694262 Not yet recruiting Endometrial Cancer Medical College of Wisconsin April 1 2019 Phase 2
NCT03694262 Not yet recruiting Endometrial Cancer Medical College of Wisconsin April 1 2019 Phase 2
NCT03840200 Not yet recruiting Breast Cancer|Prostate Cancer|Ovarian Cancer Hoffmann-La Roche March 22 2019 Phase 1|Phase 2
NCT03795272 Not yet recruiting Cervical Cancer Nordic Society for Gynaecologic Oncology|Institute of Cancer Research United Kingdom|Central and Eastern European Oncology Group|North Eastern Germany Society of Gynaecologic Oncology|Belgian Gynaecological Oncology Group|Princess Margaret Hospital Canada|PGOG (Polish Gynaecologic Oncology Group)|GSO Global Clinical Research BV|GCP-enhederne March 1 2019 Phase 2
NCT03639935 Recruiting Biliary Tract Cancer University of Michigan Rogel Cancer Center|Dana-Farber Cancer Institute|Vanderbilt University Medical Center March 2019 Phase 2
NCT03617679 Recruiting Metastatic Endometrial Cancer University of Colorado Denver|Clovis Oncology Inc.|National Cancer Institute (NCI) March 6 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PARPシグナル伝達経路

PARP Inhibitors with Unique Features

相関PARP製品

Tags: Rucaparib (AG-014699,PF-01367338) phosphateを買う | Rucaparib (AG-014699,PF-01367338) phosphate ic50 | Rucaparib (AG-014699,PF-01367338) phosphate供給者 | Rucaparib (AG-014699,PF-01367338) phosphateを購入する | Rucaparib (AG-014699,PF-01367338) phosphate費用 | Rucaparib (AG-014699,PF-01367338) phosphate生産者 | オーダーRucaparib (AG-014699,PF-01367338) phosphate | Rucaparib (AG-014699,PF-01367338) phosphate化学構造 | Rucaparib (AG-014699,PF-01367338) phosphate分子量 | Rucaparib (AG-014699,PF-01367338) phosphate代理店
×

平素は格別のお引き立てを賜り厚くお礼申し上げます。
国内在庫の無い製品の輸入手配は通常、毎週木曜12時で締め切らせていただいておりますが、
9月第2週の輸入手配に関しましては都合により締切日を9月10日(火)12時とさせていただきます。
お客様には大変ご不便をお掛けいたしますが、よろしくお願い申し上げます。

×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID